Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management—A Narrative Review
Journal of Clinical Medicine · 24.01.2025 · 14 (3) · 762
DOI: 10.3390/jcm14030762 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.01.2025. Verfasst von Denisa Maria Mitroi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, University of Medicine and Pharmacy, 200349 Craiova, Romania. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova, Romania.
Abstract (Originalsprache)
Tuberculosis (TB) induces a hypercoagulable state characterized by systemic inflammation, endothelial dysfunction, and alterations in the coagulation and fibrinolytic pathways. This review explores the pathophysiological mechanisms underlying hypercoagulability in TB, including increased pro-inflammatory cytokine release, endothelial damage, platelet activation, and reduced anticoagulant and fibrinolytic activity. These factors contribute to an elevated risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), which complicate TB prognosis and treatment. The potential role of adjunctive anti-inflammatory therapies, such as vitamin D, NSAIDs, corticosteroids, and anti-platelet agents, is highlighted as a strategy to mitigate systemic inflammation and reduce thrombotic risks in patients with TB. The challenges of anticoagulation therapy, particularly in managing the interactions between anti-TB medications and traditional anticoagulants, are discussed, along with the potential of novel oral anticoagulants (NOAs) as alternatives. We also address therapy of hypercoagulability in TB within resource-limited settings which requires low-cost diagnostics, accessible anticoagulation options, adjunctive therapies, and preventive strategies integrated into existing healthcare systems. Effective risk stratification and individualized management strategies are vital for reducing the morbidity and mortality associated with thrombotic complications in TB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School, University of Medicine and Pharmacy, 200349 Craiova, Romania.
- Department of Pulmonology, Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
- Pneumology Department, University of Medicine and Pharmacy, 200349 Craiova, Romania.
- Department of Physiology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Microbiology Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Oral-Dental Prevention, University of Medicine and Pharmacy, 200349 Craiova, Romania.
ORCID-Profile: Mara Amalia Balteanu, Ramona Cioboata, Silviu Gabriel Vlasceanu, Ovidiu Mircea Zlatian, Oana Maria Catana, Adina Andreea Mirea, Viorel Biciusca
Förderung
- University of Medicine and Pharmacy of Craiova, Romania
Zitieren
APA
Mitroi, D. M., Balteanu, M. A., Cioboata, R., Vlasceanu, S. G., Zlatian, O. M., Catana, O. M., Mirea, A. A., Mogos, G. F. R., Rotaru, I., & Biciusca, V. (2025). Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management—A Narrative Review. Journal of Clinical Medicine, 14(3), 762. https://doi.org/10.3390/jcm14030762
Vancouver
Mitroi DM, Balteanu MA, Cioboata R, Vlasceanu SG, Zlatian OM, Catana OM, et al. Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management—A Narrative Review. Journal of Clinical Medicine. 2025;14(3):762. doi:10.3390/jcm14030762
BibTeX
@article{Mitroi2025,
author = {Mitroi, Denisa Maria and Balteanu, Mara Amalia and Cioboata, Ramona and Vlasceanu, Silviu Gabriel and Zlatian, Ovidiu Mircea and Catana, Oana Maria and Mirea, Adina Andreea and Mogos, Gabriel Florin Razvan and Rotaru, Ionela and Biciusca, Viorel},
title = {Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management—A Narrative Review},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {3},
pages = {762},
doi = {10.3390/jcm14030762}
}
EUVIMED